December 30, 2025

IDEAYA Biosciences (IDYA) Investor Outlook: Exploring a 42.5% Potential Upside in the Precision Oncology Space

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is making waves in the biotechnology sector with its focus on precision medicine and oncology. As a company dedicated to the discovery and development of..

QuidelOrtho Corporation (QDEL) Stock Analysis: Navigating Potential Upside of 28.56% Amidst Market Challenges

QuidelOrtho Corporation (QDEL), a leading name in the healthcare sector specializing in medical devices, offers a compelling case for investors seeking opportunities in the diagnostic testing solutions market. With a..

Acadia Healthcare Company, Inc. (ACHC) Stock Analysis: A 46% Upside Potential Amidst Healthcare Expansion

Acadia Healthcare Company, Inc. (ACHC), a prominent player in the healthcare sector, is drawing significant investor attention with its potential upside of 46.31%. Headquartered in Franklin, Tennessee, Acadia specializes in..

Immunocore Holdings plc (IMCR) Stock Analysis: A Biotechnology Pioneer with 80% Upside Potential

Immunocore Holdings plc (NASDAQ: IMCR) is making waves in the biotechnology sector with its cutting-edge approach to immunotherapy. With a market cap of approximately $1.79 billion, this UK-based company is..

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Assessing Future Growth in the Medical Devices Sector

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a pivotal player in the healthcare sector, specifically within the medical devices industry. Headquartered in San Diego, California, Tandem specializes in innovative technology..

Twist Bioscience Corporation (TWST) Stock Analysis: Unveiling a 9.21% Potential Upside in Synthetic DNA Innovation

Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in the healthcare sector specializing in diagnostics and research, is capturing the attention of investors with its innovative strides in synthetic DNA..

PACS Group, Inc. (PACS) Stock Analysis: A Healthcare Powerhouse with a 9% Upside Potential

PACS Group, Inc. (NASDAQ: PACS), a burgeoning name in the healthcare sector, is redefining the landscape of medical care facilities in the United States. With a market capitalization of $6.11..

Disc Medicine, Inc. (IRON) Stock Analysis: Poised for 55% Upside Potential Amid Robust Analyst Confidence

Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to addressing serious hematologic diseases. With a market capitalization of..

ICU Medical, Inc. (ICUI) Investor Outlook: Analyzing a 22.82% Potential Upside Amidst Market Volatility

ICU Medical, Inc. (NASDAQ: ICUI) presents a compelling investment narrative within the healthcare sector, specifically in the medical instruments and supplies industry. With a market capitalization of $3.63 billion, the..

Bausch Health Companies Inc. (BHC) Stock Analysis: A Closer Look at Its Potential Upside and Financial Health

Bausch Health Companies Inc. (NYSE: BHC) stands out in the healthcare sector as a diversified specialty pharmaceutical and medical device company. Operating from Laval, Canada, Bausch Health’s market capitalization currently..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Exploring the 24.98% Upside Potential

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is making waves in the biotechnology sector with a remarkable 24.98% potential upside, capturing the attention of savvy investors looking for promising opportunities in the..

LeMaitre Vascular, Inc. (LMAT) Investor Outlook: A 24.96% Upside Potential Amidst Strong Revenue Growth

LeMaitre Vascular, Inc. (NASDAQ: LMAT), a stalwart in the healthcare sector, particularly in medical instruments and supplies, offers a compelling prospect for investors seeking exposure to the vascular surgery market...

Zai Lab Limited (ZLAB): Analyst Ratings Reveal 175.93% Potential Upside for This Biotech Powerhouse

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the biotechnology sector, has captured investor attention with its robust pipeline and strategic partnerships. Based in China, Zai Lab focuses on..

HUTCHMED (China) Limited (HCM): Investor Outlook Highlights 68.54% Potential Upside

HUTCHMED (China) Limited (NASDAQ: HCM), a prominent player in the healthcare sector, offers a compelling opportunity for investors seeking exposure to the precision medicine market, particularly in oncology. With its..

Organon & Co. (OGN) Stock Analysis: A Closer Look at Its 31.61% Potential Upside and What It Means for Investors

Organon & Co. (OGN), a prominent player in the healthcare sector specializing in drug manufacturing, presents an intriguing opportunity for investors seeking both stability and potential upside. With a market..

Galapagos NV (GLPG) Stock Analysis: Navigating a 16% Potential Downside Amidst Biotech Innovations

Galapagos NV (Nasdaq: GLPG), a Belgium-based biotechnology firm, stands at a pivotal moment for investors keen on the healthcare sector. With a market capitalization of $2.18 billion, Galapagos is not..

Perrigo Company plc (PRGO) Stock Analysis: Exploring a Potential 50% Upside with a High Dividend Yield

Perrigo Company plc (NYSE: PRGO), a prominent player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry, presents an intriguing opportunity for investors. With its headquarters..

Concentra Group Holdings Parent (CON) Stock Analysis: A Healthcare Play with 41% Upside Potential

Concentra Group Holdings Parent, Inc. (CON), a key player in the healthcare sector, is garnering significant attention from investors seeking robust growth prospects. With a current market capitalization of $2.58..

Kiniksa Pharmaceuticals (KNSA) Investor Outlook: Exploring a Promising 33% Upside

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) is capturing investor attention with its impressive growth potential and robust pipeline of novel therapies targeting diseases with unmet medical needs. With a current market..

CRISPR Therapeutics AG (CRSP) Stock Analysis: Exploring a 50.70% Potential Upside in Gene Editing Innovations

CRISPR Therapeutics AG (NASDAQ: CRSP), a pioneering entity in the realm of gene editing, is capturing investor attention with its cutting-edge CRISPR/Cas9 technology. Operating within the biotechnology sector, this Swiss..

Search

Funds

December 30, 2025

Search

Funds

December 30, 2025

FTSE 100

Funds